Simplify Logo

Full-Time

Future Consideration

Posted on 10/23/2024

Freenome

Freenome

501-1,000 employees

Biotechnology company for early cancer detection

Biotechnology
Healthcare

Entry

Daly City, CA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Requirements
  • passionate about Freenome's mission
  • ability to prioritize, manage, and execute goals in alignment with company goals
  • embrace values of empathy, integrity, and trust
  • hold themselves and their team accountable
  • crave collaboration with brilliant minds from unfamiliar fields of study
  • believe that hiring and mentorship are fundamental to success
  • welcome and provide constructive feedback and criticism
  • trust in the good intentions of others
  • secure in the knowledge that embracing mistakes is the best way to learn and move on
Responsibilities
  • contribute in a meaningful way to Freenome's mission
  • work collaboratively with team members
  • engage in problem-solving and uncovering opportunities
  • impact the lives of millions of people affected by cancer

Freenome focuses on improving cancer detection through advanced blood tests. The company uses a multiomics approach, analyzing various biological data types, including genomics and proteomics, to find cancer markers in blood samples. This method allows for non-invasive early detection of cancer, which is crucial for effective treatment. Freenome differentiates itself from competitors by its unique combination of data analysis techniques and its commitment to clinical trials and research collaborations, which enhance the reliability of its tests. The goal of Freenome is to provide healthcare providers and research institutions with accurate diagnostic tools that can lead to earlier cancer detection, ultimately improving patient outcomes.

Company Stage

Series D

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-13%

1 year growth

-9%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Freenome's recent $254 million funding round will accelerate its platform capabilities and expand clinical trials, offering significant growth opportunities.
  • The initiation of the PROACT LUNG study for early lung cancer detection highlights Freenome's commitment to expanding its diagnostic capabilities beyond colorectal cancer.
  • Partnerships with major entities like Walgreens enhance Freenome's reach and credibility in the healthcare sector.

What critics are saying

  • The recent layoff of 100 employees could indicate financial instability or strategic misalignment, affecting employee morale.
  • The highly competitive landscape of cancer diagnostics requires continuous innovation to maintain a leading position.

What makes Freenome unique

  • Freenome's unique multiomics approach, combining genomics and proteomics, sets it apart from competitors who may focus on single data types.
  • The company's significant funding, including a recent $270 million investment, underscores strong investor confidence and provides a financial edge over less-funded competitors.
  • Freenome's collaborative culture and commitment to diversity, equity, and inclusion foster a unique work environment that attracts top talent.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO